Skip to main content
915 TLDR
Health
1 read

Concerns Rise Over US-UK Pharma Deal's Impact on Health in England

KVIACNN Newsource
Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

Read Original

AI Summary

A recent analysis warns that a trade agreement between the US and UK could lead to over 229,000 preventable deaths in England by reallocating funds from essential health services. The UK plans to increase its spending on new medicines from 0.3% to at least 0.6% of GDP over the next decade, costing the National Health Service (NHS) an estimated £45 billion ($60 billion) by 2036. Critics argue that this financial strain will exacerbate health inequalities, particularly affecting those with chronic conditions. The UK government has hailed the deal as a means to secure access to medicines, but experts question its economic benefits given the UK's status as a net importer of pharmaceuticals.

Key Details: • UK's NHS could face an additional £45 billion cost by 2036 due to the deal. • Projected 229,000 avoidable deaths mainly among patients with heart, respiratory, and gastrointestinal diseases. • The UK government must find extra funding to prevent service cuts and health inequalities.

healthcare pharmaceuticals uk trade-deal nhs

People & Organizations

University of YorkNational Health ServiceUniversity of LiverpoolChristchurch Hospital

Related Articles